Nektar Therapeutics Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Nektar Therapeutics (NKTR) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $251.76 million as of 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2013-03-01
- 2012-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $251.76M.
- 2012-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $308.94M.
- 2012-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $296.72M.
- 2012-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $233.62M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2012-12-31 | $251.76M 10-K · filed 2013-03-01 |
| 2012-09-30 | $308.94M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $296.72M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $233.62M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $213.39M 10-K · filed 2013-03-01 |
| 2010-12-31 | $298.18M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |